Patient-reported outcomes in metastatic castration-resistant prostate cancer
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Patient-reported outcomes in metastatic castration-resistant prostate cancer
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume 13, Issue 10, Pages 643-650
Publisher
Springer Nature
Online
2016-06-29
DOI
10.1038/nrclinonc.2016.100
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
- (2016) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)
- (2015) N. I. Cherny et al. ANNALS OF ONCOLOGY
- Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279)
- (2015) Amit Bahl et al. BJU INTERNATIONAL
- Inclusion of patient-reported outcome measures in registered clinical trials: Evidence from ClinicalTrials.gov (2007–2013)
- (2015) E. Vodicka et al. Contemporary Clinical Trials
- Development of a Standardized Set of Patient-centered Outcomes for Advanced Prostate Cancer: An International Effort for a Unified Approach
- (2015) Alicia K. Morgans et al. EUROPEAN UROLOGY
- Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients
- (2015) Orazio Caffo et al. Future Oncology
- Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial
- (2015) Yohann Loriot et al. LANCET ONCOLOGY
- Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trial
- (2014) D. Cella et al. ANNALS OF ONCOLOGY
- 177Lu-EDTMP for palliation of pain from bone metastases in patients with prostate and breast cancer: a phase II study
- (2014) Krishan Kant Agarwal et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Recommended Patient-Reported Core Set of Symptoms to Measure in Prostate Cancer Treatment Trials
- (2014) Ronald C. Chen et al. JNCI-Journal of the National Cancer Institute
- Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial
- (2014) Karim Fizazi et al. LANCET ONCOLOGY
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial
- (2013) A. Bahl et al. ANNALS OF ONCOLOGY
- Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy
- (2013) Stephen Harland et al. EUROPEAN JOURNAL OF CANCER
- Reporting of Patient-Reported Outcomes in Randomized Trials
- (2013) Melanie Calvert et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial
- (2013) Ethan Basch et al. LANCET ONCOLOGY
- Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid
- (2013) Roger von Moos et al. SUPPORTIVE CARE IN CANCER
- Prevalence of Pain and Analgesic Use in Men With Metastatic Prostate Cancer Using a Patient-Reported Outcome Measure
- (2013) Karen A. Autio et al. Journal of Oncology Practice
- Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy
- (2012) C. N. Sternberg et al. ANNALS OF ONCOLOGY
- Quality of Life Associated with Treatment of Castration-Resistant Prostate Cancer: A Review of the Literature
- (2012) Judd W. Moul et al. CANCER INVESTIGATION
- A randomized, dose–response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer
- (2012) S. Nilsson et al. EUROPEAN JOURNAL OF CANCER
- A Randomized, Double-Blind, Dose-Finding, Multicenter, Phase 2 Study of Radium Chloride (Ra 223) in Patients with Bone Metastases and Castration-Resistant Prostate Cancer
- (2012) Christopher C. Parker et al. EUROPEAN UROLOGY
- Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial
- (2012) Christopher J Logothetis et al. LANCET ONCOLOGY
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Integration of immunotherapy into the management of advanced prostate cancer
- (2012) Philip Kantoff et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Reasons for Rejection of Patient-Reported Outcome Label Claims: A Compilation Based on a Review of Patient-Reported Outcome Use among New Molecular Entities and Biologic License Applications, 2006–2010
- (2012) Carla DeMuro et al. VALUE IN HEALTH
- Impact of docetaxel-based chemotherapy on quality of life of patients with castration-resistant prostate cancer: results from a prospective phase II randomized trial
- (2011) Orazio Caffo et al. BJU INTERNATIONAL
- Pain in castration-resistant prostate cancer with bone metastases: a qualitative study
- (2011) Adam Gater et al. Health and Quality of Life Outcomes
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reliability of adverse symptom event reporting by clinicians
- (2011) Thomas M. Atkinson et al. QUALITY OF LIFE RESEARCH
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- The Missing Voice of Patients in Drug-Safety Reporting
- (2010) Ethan Basch NEW ENGLAND JOURNAL OF MEDICINE
- Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study
- (2008) Dominik R. Berthold et al. JOURNAL OF CLINICAL ONCOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started